Notice for lenvatinib (as mesilate) (Eisai Australia Pty Ltd)
Active ingredients
lenvatinib (as mesilate)
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Therapeutic area
Oncology